Howley Evey, Davies E Graham, Kreins Alexandra Y
Department of Immunology and Gene Therapy, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Infection, Immunity and Inflammation Research & Teaching Department, University College London, London, UK.
Ther Clin Risk Manag. 2023 Mar 13;19:239-254. doi: 10.2147/TCRM.S379673. eCollection 2023.
Inborn errors of thymic stromal cell development and function which are associated with congenital athymia result in life-threatening immunodeficiency with susceptibility to infections and autoimmunity. Athymic patients can be treated by thymus transplantation using cultured donor thymus tissue. Outcomes in patients treated at Duke University Medical Center and Great Ormond Street Hospital (GOSH) over the past three decades have shown that sufficient T-cell immunity can be recovered to clear and prevent infections, but post-treatment autoimmune manifestations are relatively common. Whilst thymus transplantation offers the chance of long-term survival, significant challenges remain to optimise the outcomes for the patients. In this review, we will discuss unmet needs and offer practical guidance based on the experience of the European Thymus Transplantation programme at GOSH. Newborn screening (NBS) for severe combined immunodeficiency (SCID) and routine use of next-generation sequencing (NGS) platforms have improved early recognition of congenital athymia and increasing numbers of patients are being referred for thymus transplantation. Nevertheless, there remain delays in diagnosis, in particular when the cause is genetically undefined, and treatment accessibility needs to be improved. The majority of athymic patients have syndromic features with acute and chronic complex health issues, requiring life-long multidisciplinary and multicentre collaboration to optimise their medical and social care. Comprehensive follow up after thymus transplantation including monitoring of immunological results, management of co-morbidities and patient and family quality-of-life experience, is vital to understanding long-term outcomes for this rare cohort of patients. Alongside translational research into improving strategies for thymus replacement therapy, patient-focused clinical research will facilitate the design of strategies to improve the overall care for athymic patients.
与先天性无胸腺症相关的胸腺基质细胞发育和功能的先天性缺陷会导致危及生命的免疫缺陷,易受感染和自身免疫影响。无胸腺症患者可通过使用培养的供体胸腺组织进行胸腺移植来治疗。过去三十年在杜克大学医学中心和大奥蒙德街医院(GOSH)接受治疗的患者结果表明,足够的T细胞免疫功能可以恢复以清除和预防感染,但治疗后自身免疫表现相对常见。虽然胸腺移植提供了长期生存的机会,但仍存在重大挑战,需要优化患者的治疗结果。在本综述中,我们将讨论尚未满足的需求,并根据GOSH欧洲胸腺移植项目的经验提供实用指导。对严重联合免疫缺陷(SCID)进行新生儿筛查(NBS)以及常规使用下一代测序(NGS)平台改善了对先天性无胸腺症的早期识别,越来越多的患者被转诊进行胸腺移植。然而,诊断仍存在延迟,特别是当病因在基因上不明确时,并且治疗的可及性需要改善。大多数无胸腺症患者具有综合征特征,伴有急性和慢性复杂健康问题,需要终身多学科和多中心合作以优化其医疗和社会护理。胸腺移植后的全面随访,包括监测免疫结果、管理合并症以及患者和家庭的生活质量体验,对于了解这一罕见患者群体的长期结果至关重要。除了对改善胸腺替代治疗策略的转化研究外,以患者为中心的临床研究将有助于设计改善无胸腺症患者整体护理的策略。